ISSN: 0974-2115
www.jchps.com Journal of Chemical and Pharmaceutical Sciences

Synthesis, Analgesic and Anti-Inflammatory Activity of Novel 3-(Thiophen-2-Yl) -Pyrazoline-5-Yl Derivatives

Biswajit Dash, Uttam Borah*, Suvakanta Dash
Girijananda Chowdhury Institute of Pharmaceutical Science, Azara, Guwahati-781017
***Corresponding author: E-Mail: borahuttam@yahoo.in, Mobile- +91-8876562782**

ABSTRACT

Ten subsidiaries of N_1 substituted/unsubstituted 5-(4-chlorophenyl)- 3-(2-thienyl) pyrazoline were integrated from chalcone-like moderate and substituted phenyl hydrazines, hydrazine hydrate, and semi/thiosemicarbazide. The synthetic structure of mixes was affirmed by methods for IR, ^{1}HNMR, mass spectroscopy, and elemental analysis investigation. The pain relieving and mitigating action were researched by tail immersion technique and carrageenan-actuated paw oedema strategy individually. Among the synthesized subordinates, compound IId (5-[(4-chlorophenyl)- 1-(4-methoxyphenyl)]-3-thiophen-2-yl)- 4,5-dihydro-2-pyrazoline), IIg (5-(4-chlorophenyl)- 1-(2-methylphenyl)- 3-(thiophen-2-yl)- 4,5-dihydro-2-pyrazoline) display great pain relieving and mitigating properties. Compound IIi (5-(4-chlorophenyl)- 1-thiocarbamoyl-3-(thiophen-2-yl))- 2-pyrazoline) and IIj (5-(4-chlorophenyl)- 1-carbamoyl-3-(thiophen-2-yl))- 2-pyrazoline) display mellow to direct pain-relieving and calming properties. The fundamental goal of the present research is to build up some novel pyrazoline subsidiaries and assess their conceivable pain relieving and mitigating standard.

KEY WORDS: Chalcone, Pyrazoline, analgesic and anti-inflammatory activity.

1. INTRODUCTION

Pain and inflammation are one of the pervasive conditions that point of confinement profitability and decrease individual fulfilment. Many medications are utilized as analgesics and mitigating specialists. Over the latest couple of decades, there are numerous NSAIDs are set up yet they are having some symptom. Heterocyclic mixes having nitrogen in the ring are having an extensive scope of characteristic activity.

Compounds with pyrazoline ring have become extensive thought of late. They have been represented as having a broad assortment of activities such as anti-inflammatory (Fioravanti, 2010), antidepressant (Rajendra, 2005), anticonvulsant (Dhanawat, 2012), Ant tubercular (Ali, 2007), Anti-diabetic (Bertrand, 2002), anti-androgenic (Amr, 2006), anti-thrombotic (Casimiro, 2006) properties.

Cyclooxygenases (COX) are the primary compounds required in the biosynthetic pathway of prostaglandins (PGs), thromboxane and prostacyclins. The cyclooxygenase compound exists in two unmistakable isoforms: Cyclooxygenase-1 and Cyclooxygenase-2. Correlation of COX-1 and COX-2 prompts 60% personality of the arrangement. Single peptide of COX-2 is seven build-ups shorter than that of COX-1. The C-end of COX-2 has 18-buildup inclusion while the N-end of COX-1 has 8-deposit addition. COX-1 is constitutive and is vital for cytoprotection of gastrointestinal tract, platelet collection and renal blood stream. In any case, COX-2 is inducible and communicated amid irritation, torment and oncogenesis. They are initiated by star provocative atoms like lipopolysaccharide, tumour corruption consider, interleukin, carrageenan and so on.

Non-steroidal calming drugs locate the most clinical. Significance in the administration of irritation, torment and fever. These medications apply mitigating action and soothe irritation related torment by the cooperating and restraining the enzymatic movement prompting the hindrance of prostaglandins. In any case, the traditional NSAIDs like headache medicine, indomethacin are nonselective regarding both isoforms. Headache medicine represses COX-1 emphatically than COX-2 and hindrance of COX-1 diminishes creation of PGE2and PGI2 which brings about ulcerogenic effect. The unique confining favouritism of built up NSAIDs to COX-1 prompts framework based responses like gastrointestinal ulcerations, dyspepsia and nephrotoxicity. The divulgence of COX-2, imparted due to flammable jars, appear in the central tangible framework, not in the gastric mucosa has given an exceptional opportunity to make NSAIDs that don't have the ulcerogenic affect.

Composing study review uncovers that the 2-pyrazoline subordinates have engaged generous consideration from restorative physicists. 2-pyrazoline is a vital framework since a few 2-pyrazoline subordinates are observed to be related to extensive variety of organic exercises like antimicrobial, anti-amoebic, antimycobacterial, antiviral, analgesic, anti-inflammatory, antinociceptive, anticancer, antioxidant, hypotensive anti-convulsant, antidepressant and so on. Numerous pyrazoline subordinates have picked up either clinical application as NSAIDs. Antipyrine (2, 3-dimethyl-1-phenyl-3-pyrazolin-5-one) was the main pyrazolin derivative utilized as a part of the administration irritation and torment. Phenylbutazone and its metabolite oxyphenbutazone pyrazolinedione subsidiaries having strong mitigating movement. In any case, they wound up plainly limited because of the GI symptoms. A few pyrazolidine-3, 5-diones, pyrazolin-5-ones and pyrazolin-3-ones are accessible as NSAID e.g. felcobuzone, famprofazone, morazone, mefobutazone and ramifenazone.

Particular COX2 inhibitors are needed carboxylate group unlike the classical NSAIDs. Other than these numerous pyrazoline subsidiaries are accounted for in the writing as powerful calming and pain relieving specialist. According to writing survey the pyridine, naphthalene, furan, thiophene subsidiaries likewise have pain relieving and against inflammatory activities. Empowered by these certainties it was wanted to blend 2-pyrazoline subordinates containing pyridyl/napthyl, furyl/thienyl/4-nitrophenyl and 4-chlorophenyl/4-hydroxyphenyl gathers as substituents without the nearness of carboxylate gathering since fuse of an acidic gathering brings about the poor selectivity towards COX2. The integrated twelve 2-pyrazoline subsidiaries were portrayed by IR, H-NMR, Mass spectroscopy and were found to have a fascinating profile of calming, pain relieving action with the critical diminishment in their ulcerogenic potential when contrasted with the standard medication (Dipankar, 2012).

The present review was meant to build up some novel pyrazoline subordinates and assess their conceivable pain-relieving and calming movement.

2. MATERIAL AND METHODS

All reagents and solvents utilized as a part of the experiment were of scientific grade and acquired from Sigma–Aldrich (India). The advance of the response was checked by thin layer chromatography with hexane/ethyl acetic acid derivation (ϕr = 3: 2) as the portable stage and performed on Merck silica gel 60 F254 aluminium sheets (Merck, Germany); the items were cleaned by re-crystallization. Dissolving focuses were resolved in open vessels utilizing Stuart SMP10 (Barloworld Scientific Ltd., UK), electrothermal liquefying point mechanical assembly and were not revised. IR spectra were recorded on a Shimadzu 8400S FTIR (Shimadzu Corporation, Japan) spectrophotometer utilizing KBr pellets and were recorded in cm−1. ^{1}H NMR (300 MHz) spectra were procured on a JEOL AL300 FT-NMR (Jeol Ltd., Japan) in CDCl3 utilizing TMS as the inward standard and the concoction movements were accounted for in δ. The mass range was gotten on a Hewlett Packard show GCD-1800A (Hewlett Packard, USA) electron affect mass spectrometer at 70 eV ionizing shaft and utilizing an immediate addition test. Essential examinations for C, H, and N have performed on Exeter CE-440 (Hewlett–Packard, USA) basic analyser.

Analgesic activity evaluation: The pain-relieving activity of the synthesized compounds was assessed by tail flick technique. Wistar rats (n=6) were gathered by irregular examining method for the review. Diclofenac sodium at the dosage of 10 mg/kg (p.o.) was treated as the control for examination. The test compounds were inserted by the oral courses at the measurement level of 200 mg/kg b.w. The rats were held in position by an appropriate restrained with the tail reaching out and the tail (up to 6 cm) was taken and plunged in a measuring glass. In that beaker, water ought to be kept up at 56 ± 4^{0}C. The time in sec taken by the rats to pull back their tail totally out of the water was taken these are the response time. The perception was done at 0, 90, 120, 180 min after the organization of our integrated mixes. A cut-off purpose of 15 sec was seen to stay away from the tail harm. The rate pain relieving movement was effortlessly figured by the beneath said equation.

PAA = [(B-A)/B] X 100%

B - Reaction time in sec after treatment A -Reaction time in sec before treatment

PAA - Percentage analgesic activity.

Anti-Inflammatory Activity Study (Dipankar, 2012): Assessment of anti-inflammatory action was completed via Carrageenan actuated rear paw edema in rats by the technique for C.A. Winter et.al.103 the creatures were arbitrarily partitioned into gatherings of 6 creatures and were fasted for 24 hours before the test. The control gather got just 0.5% carboxy methyl cellulose arrangement. Diclofenac sodium (13.5 mg/kg) was controlled intra peritoneally as standard medication for comparisons. The incorporated mixes were directed at two measurement levels (100 and 200 mg/kg). Carrageenan arrangement 0.1 ml (1% in clean 0.9% NaCl arrangement) were infused subcutaneously into the sub grower district of the correct rear paw of each rat,1 hour before the organization of the standard and test drugs. The correct rear paw volumes were measured previously, then after the fact 120, 180 and 240 min after organization with the guide of plethysmometer.

The rate of edema hindrance was computed from the mean impact in the control and treated creatures agreeing on the accompanying condition. Percent edema inhibition = (V_C-V_t/ V) x 100

V_t = Mean increase in the paw volume in rats tested with test compound.

V_c= Mean increase in the paw volume in control group of rats.

Experimental methods:

Synthesis:

Synthesis of (E)-3-(4-chlorophenyl)-1-(thiophen-2-yl) prop-2-en-1-one (I):

Intermediate: Equimolar fixations (0.04 mole) of 1-thiophen-2-yl-ethanone and 4-chlorobenzaldehyde were added to the 10 % watery arrangement of NaOH and ethanol (30mL) with a specific end goal to complete Claisen–Schmidt build up. The response blend was then mixed at room temperature for 3 h and the item, in this manner got was separated, dried, and re-solidified from ethanol.

General procedure for the synthesis of pyrazoline derivatives:

Synthesis of compounds IIa–IIh: Equimolar fixations (0.1 mole) of I and 2, 4-substituted phenyl hydrazine and hydrazine hydrate in ethanol were refluxed for 4h. The response blend was then filled super cold water and the accelerate so got was washed with water, dried, and recrystallized from ethanol to manage the cost of the target mixes IIa–IIh.

Synthesis of compounds IIi–IIj: A blend of compound I (1.0 mol) and semi/thiosemicarbazide (1.0 mol) in ethanolic NaOH (0.02 mol, 50 mL) was refluxed for around 2 h. The response blend was then filled super cold water and the encourage so got was isolated by filtration, washed with water, dried, and re-solidified from ethanol to bear the cost of the targete mixes IIi and IIj.

Pharmacological activity: Every one of the chemicals and solvents utilized for the pharmacological action was bought from Sigma-Aldrich. The recently synthesize compounds (IIa-IIj) were tried for their pain-relieving and anti-inflammatory movement.

3. RESULT AND DISCUSSION

Spectral characterisation: The proposed subsidiaries were combined as delineated in fig.2. Physical properties and elemental examination and additionally all the spectral information are as per the structures of the integrated compounds appeared in table.1 and 2. The spectra of I showed the trademark —C=O stretching at 1708 cm^{-1} and a sharp peak at 1658 cm^{-1} due to α, β —CH=CH. The subordinates indicated symptomatic infrared assimilations at 1578–1598 cm^{-1} for —C=N stretching of the pyrazoline nucleus.



Figure.1. Scaffold of the designed pyrazoline derivatives



Figure.2. Synthesis of Compound IIa-IIj

Table.1. Physico-chemical Charaterisation

Comp Code	Mol. Formula	Mol.wt	Wi (Calc.)/%, Wi (Found)/%			Yield (%)	MP(0°C)
			C	H	N		
I	$C_{13}H_9ClOS$	248.81	62.78	3.65	----	82	104-106
			63.01	3.62	----		
IIa	$C_{19}H_{15}ClN_2S$	338.12	67.35	4.46	8.27	71	135-137
			67.53	4.61	8.25		
IIb	$C_{19}H_{14}Cl_2N_2S$	372.67	61.13	3.78	7.50	69	130-132
			60.92	3.65	7.48		
IIc	$C_{19}H_{14}BrClN_2S$	417.38	54.63	3.38	6.71	70	121-123
			54.81	3.37	6.69		

IId	$C_{20}H_{17}ClN_2OS$	368.74	65.12	4.65	7.59	67	140-142
			64.89	4.63	7.56		
IIe	$C_{19}H_{14}ClN_3O_2S$	383.09	59.45	3.68	10.95	63	137-139
			59.53	3.69	10.91		
IIf	$C_{19}H_{14}Cl_2N_2S$	372.12	61.13	3.78	7.50	66	125-127
			61.24	3.79	7.48		
IIg	$C_{20}H_{17}ClN_2S$	352.21	68.07	4.86	7.94	68	134-136
			67.42	4.84	7.96		
IIh	$C_{13}H_{11}ClN_2S$	362.13	59.42	4.22	10.66	70	133-135
			59.27	4.29	10.68		
IIi	$C_{14}H_{12}ClN_3S_2$	321.04	52.25	3.76	13.06	75	180-182
			52.06	3.75	13.01		
IIj	$C_{14}H_{12}ClN_3OS$	305.06	54.99	3.96	13.74	87	195-198
			54.85	3.97	13.77		

Table.2. Spectral Characterisation of Newly Prepared Compounds

Compound	Spectral data
I	IR, υ˜/cm^{-1}: 855 (C-Cl stretching), 1658 (α, β CH=CH), 1708 (C=O). ^{1}H-NMR ($CDCl_3$), δ: 6.65 (d, 1H,-CO-CH=), 7.20-7.68 (m, 7H, Ar-H and thiophene), 7.81 (d, 1H, =CH-Ar). MS, m/z: 248.81 (M^+)
IIa	IR, υ˜/cm^{-1}: 1069 (C5-N1 stretching), 1373 (C4-H deformation), 1591 (C=N), 3010 (CH thienyl). ^{1}H-NMR ($CDCl_3$),δ: 3.05 (1H, dd, Ha), 3.89 (1H, dd, Hb), 5.26 (1H, dd, Hx), 6.93–7.71 (12H, m, thiophene and Ar-H).MS, m/z: 338.12 (M^+)
IIb	IR, υ˜/cm^{-1}: 1076 (C5-N1 stretching), 1089 (C-S-C stretching), 1383 (C4-H deformation), 1597 (C=N), 3012 (CH thienyl). ^{1}H-NMR ($CDCl_3$), δ: 3.07 (1H, dd, Ha), 3.83 (1H, dd, Hb), 5.21 (1H, dd, Hx), 6.94–7.68 (11H, m, thiophene and Ar-H).MS, m/z: 372.67 (M^+)
IIc	IR, υ˜/cm^{-1}: 1081 (C5-N1 stretching), 1085 (C-S-C stretching), 1367 (C4-H deformation), 1593 (C=N), 3050 (CH thienyl).^{1}H-NMR ($CDCl_3$),δ:3.07 (1H, dd, Ha), 3.86 (1H, dd, Hb), 5.24 (1H, dd, Hx), 6.85–7.64 (11H, m, thiophene and Ar-H).MS, m/z: 417.38 (M^+)
IId	IR, υ˜/cm^{-1}: 1068 (C5-N1 stretching), 1082 (C-S-C stretching), 1132 (C-O stretching), 1358 (C4-H deformation), 1595 (C=N), 3041 (CH thienyl)1H-NMR ($CDCl_3$),δ:2.78(3H,s,OCH), 3.04 (1H, dd, Ha), 3.82 (1H, dd, Hb), 5.16 (1H; dd, Hx), 6.73–7.73 (11H,33m, thiophene and Ar-H). MS, m/z: 368.74 (M^+)
IIe	IR, υ˜/cm^{-1}: 1072 (C5-N1 stretching), 1088 (C-S-C stretching), 1350 (N-O stretching), 1359 (C4-H deformation), 1586 (C=N), 3017 (CH thienyl).^{1}H-NMR ($CDCl_3$),δ:3.08 (1H, dd, Ha), 3.75 (1H, dd, Hb), 5.53 (1H, dd, Hx), 7.05–7.82 (11H, m, thiophene and Ar-H). MS, m/z: 383.09 (M^+)
IIf	IR, υ˜/cm^{-1}: 1087 (C-S-C stretching), 1138 (C5-N1 stretching), 1442 (C4-H deformation), 1595 (C=N), 3045(CH thienyl).^{1}H-NMR ($CDCl_3$),δ: 3.13 (1H, dd, Ha), 3.71 (1H, dd, Hb), 5.27 (1H, dd, Hx), 6.79–7.60 (11H, m, thiophene and 3Ar-H).MS, m/z: 372.12 (M^+)
IIg	IR, υ˜/cm^{-1}: 1079 (C-S-C stretching), 1142 (C5-N1 stretching), 1378 (C4-H deformation), 1578 (C=N), 3032(CH thienyl).^{1}H-NMR ($CDCl_3$),δ:2.12(1H,s,CH), 3.10 (1H, dd, Ha), 3.78 (1H, d, Hb), 5.22 (1H, d, Hx), 6.89–7.65 (11H, m,133thiophene and Ar-H).MS, m/z: 352.21 (M^+)
IIh	IR, υ˜/cm^{-1}: 1075 (C5-N1 stretching), 1091 (C-S-C stretching), 1354 (C4-H deformation), 1597 (C=N), 3012 (CH thienyl), 3290 (NH streching). ^{1}H-NMR ($CDCl_3$),δ: 3.12 (1H, dd, Ha), 3.93 (1H, dd, Hb), 5.29 (1H, dd, Hx), 6.44–7.49 (7H, m, thiophene and Ar-H), 7.51 (1H, s, NH_2).MS, m/z: 362.13 (M^+)
IIi	IR, υ ˜/cm^{-1}: 1071 (C-S-C stretching), 1085 (C5-N1 stretching), 1345 (C=S stretching), 1425 (C4-H deformation), 1592 (C=N stretching), 3024 (CH thienyl), 3481 (NH stretching). ^{1}H-NMR ($CDCl_3$), δ: 3.12 (1H, dd, Ha), 3.81 (1H, dd, Hb), 5.98 (1H; dd, Hx), 7.07–7.63 (7H, m, thiophene and Ar-H), 7.75 (1H, s, NH_2). MS, m/z: 321.04 (M^+)
IIj	IR, υ ˜/cm^{-1}: 1072 (C-S-C stretching), 1095 (C5-N1 stretching), 1433 (C4-H deformation), 1595 (C=N stretching), 1684 (C=O stretching), 3021 (CH thienyl), 3464 (NH stretching).^{1}H-NMR ($CDCl_3$),δ: 3.08 (1H, dd, Ha), 3.84 (1H, dd, Hb), 5.29 (1H, dd, Hx), 7.04–7.52 (7H, m, thiophene and Ar-H), 7.56 (2H, s, NH_2). MS, m/z: 305.06 (M+)

Ha, Hb protons denote the methylene protons and Hx protons denote the methine proton of pyrazoline nucleus

Also, every one of the products showed C_4—H deformation (1354–1442 cm^{-1}) and C_5—N_1 stretching (1068–1142 cm^{-1}). Compounds Iii and IIj showed additional thiocarbamoyl NH stretching vibration (3481 cm^{-1}), carbamoyl

NH stretching (3464–3481 cm^{-1}), —C=S stretching at a lower frequency of 1345 cm^{-1}, and —C=O stretching at 1684 cm^{-1}. ^{1}HNMR spectra of IIa–IIj showed three spectral ranges in which each shows up as a twofold doublet because of the nearness of non-attractively equal pyrazoline Ha, Hb, and Hx protons.

The geminal pyrazoline proton in position 4 spoked to by the Ha and Hb methylene protons showed signals at δ 3.04–3.13 (upfield) and δ 3.13–3.93 (downfield), individually. The methine proton Hx seemed promote downfield at δ 5.16–5.98 and the aromatic and thienyl protons at chemical shift in the range of δ 6.44–7.82. Different protons having a place with the methyl and methoxy gatherings were seen by expected chemical shift. The natural examination results were inside ± 0.4 % of the hypothetical qualities.

Pain-releaving and anti-inflammatory activity: In the present experiment, we have screened the pain-relieving movement by tail submersion technique and calming action via carrageenan-induced paw edema strategy as appeared in the Table-3 and 4. Among the synthesized compounds, mixes IId, IIg indicated huge pain-relieving and calming movement when contrasted with the standard medication diclofenac sodium (20mg/kg) individually. This is thought to be because of the nearness of para-methoxy phenyl hydrazine aggregate and ortho-methyl phenyl hydrazine at the third position of quinazoline ring separately. Writing review demonstrated that the remedial strength is because of the nearness of alkyl or alkoxy assemble. Thus mixes containing amino gathering (IIh), semicarbamoyl aggregate (IIi), a thio-semi carbamoyl bunch (IIj) indicated great mitigating action. The movement is likely because of the nearness of electron giving substituents in the pyrazoline framework as said in the writing.

Table.3. Analgesic activity of synthesized compounds

Compound[a]	Basal Reaction Time in Second		
	0 min	15 min	
	Mean±SEM	Mean±SEM	%
IIa	1.35±0.05	3.15±0.18	57.14
IIb	1.34±0.04	2.62±0.14	48.85
IIc	1.32±0.03	2.85±0.15	53.68
IId	1.56±0.02	4.15±0.253	62.4
IIe	1.35±0.05	3.15±0.18	57.14
IIf	1.28±0.04	2.62±0.03	51.14
IIg	1.52±0.04	4.21±0.23	63.89
IIh	1.30±0.02	2.51±0.04	48.20
IIi	1.34±0.04	12±0.02	57.05
IIj	1.32±0.03	3.14±0.4	57.96
Control	1.25±0.01	1.14±0.02	----
Standard	1.78±0.07	5.35±0.34	66.72

Compound[a]	Basal Reaction Time in Second					
	30 min		60 min		120 min	
	Mean±SEM	%	Mean±SEM	%	Mean±SEM	%
IIa	4.45±0.15	69.66	5.36±0.16***	74.81	2.72±0.04	50.36
IIb	4.45±0.12	69.88	4.52±0.15***	70.35	2.62±0.05	48..85
IIc	4.25±0.19	68.94	4.75±0.07***	72.21	2.57±0.05	48.63
IId	6.42±0.12	75.7	7.95±0.15***	80.37	3.48±0.02	55.17
IIe	4.45±0.15	69.66	5.36±0.16***	74.81	2.72±0.04	50.36
IIf	4.21±0.15	69.59	4.54±0.11***	71.8	2.59±0.14	50.57
IIg	6.44±0.14	76.39	7.85±0.14***	80.89	3.45±0.03	55.94
IIh	4.26±0.12	69.48	4.48±0.15***	70.98	2.56±0.11	49.21
IIi	4.85±0.15	72.37	5.32±0.6***	74.81	2.72±0.14	50.73
IIj	4.72±0.17	72.03	5.26±0.16***	74.90	2.68±0.14	50.74
Control	1.15±0.01	----	1.6±0.03	----	1.56±0.03	----
Standard	8.5±0.15	78.39	9.64±0.14***	81.53	4.34±0.03	58.98

Table.4. Anti-inflammatory activity

Compound[a]	Time interval in minutes		
	0 min	15 min	30 min
IIa	0.14±0.002	0.16±0.0017	0.18±0.0056
IIb	0.16±0.002	0.17±0.004	0.2±0.003
IIc	0.17±0.0042	0.18±0.0057	0.21±0.005

IId	0.14±0.0018	0.16±0.0055	0.18±0.002
IIe	0.17±0.004	0.19±0.002	0.22±0.0025
IIf	0.16±0.0057	0.17±0.0046	0.2±0.003
IIg	0.17±0.0036	0.19±0.0018	0.21±0.0047
IIh	0.17±0.0041	0.18±0.0052	0.21±0.0042
Iii	0.18±0.002	0.2±0.0028	0.22±0.0024
IIj	0.15±0.003	0.18±0.0017	0.21±0.0024
Conrol	0.18±0.006	0.2±0.0095	0.24±0.007
Standard (20mg/kg)	0.12±0.005	0.14±0.007	0.18±0.0056

Compound[a]	**Time interval in minutes**			
	60 min	**120**	**180 min**	**% inhibition**
IIa	0.19±0.002	0.17±0.0047	0.15±0.004***	57.14
IIb	0.18±0.006	0.17±0.005	0.14±0.004***	60
IIc	0.23±0.007	0.19±0.002	0.15±0.004***	57.14
IId	0.2±0.003	0.17±0.004	0.11±0.0018***	68.57
IIe	0.24±0.004	0.15±0.0029	0.14±0.0045***	60
IIf	0.22±0.0024	0.18±0.006	0.15±0.0019***	57.14
IIg	0.19±0.0016	0.15±0.0026	0.13±0.0048***	65.71
IIh	0.2±0.0024	0.16±0.002	0.14±0.0019***	60
IIi	0.24±0.004	0.17±0.0038	0.12±0.005***	62.85
IIj	0.19±0.0017	0.16±0.0054	0.14±0.0038***	60
Conrol	0.27±0.008	0.31±0.009	0.35±0.008	----
Standard (20mg/kg)	0.19±0.008	0.14±0.007	0.10±0.005***	71.42

4. CONCLUSION

Another arrangement of pyrazoline subordinates with a typical skeleton was incorporated and assessed for their analgesic and anti-inflammatory properties. A couple of them are thought to guarantee mixes because of their separate exercises. Accordingly, the review merits facilitate examination, especially regarding that of the in vitro pain-relieving and anti-inflammatory movement.

REFERENCES

Ali MA, Yar MS, Kumar M, Pandian GS. Synthesis and antitubercualr activity of substituted novel pyrazoline derivatives. Natural Product Research, 21, 2007, 575-579.

Amr Ael-G, Abdel-Latif NA, Abdalla MM, Synthesis and antiandrogenic activity of some new 3- substituted androstano[17,16-c]-5'-aryl-pyrazoline and their derivatives. Bioorg Med Chem Lett, 14, 2006, 373–384.

Bertrand C, Patrick T, Christophe M, Aline P, Chenault J, Synthesis and hypoglycaemic evaluation of substituted pyrazole-4-carboxylic acids. Bioorg Med Chem Lett, 12, 2002, 2105-2108.

Casimiro-Garcia A, Dudley DA, Heemstra RJ, Filipski KJ, Bigge CF, Edmunds JJ. Progress in the discovery of factor Xa inhibitors. Exp Opi Ther Pat, 16, 2006, 119–145

Dhanawat M, Das N, Dash B, Shrivastava SK, Design, synthesis, preliminary pharmacological evaluation and docking studies of pyrazoline derivatives, Chemical Paper, 66, 2012, 67–74.

Dipankar B, Panneerselvam P and Asish B, Synthesis, Characterization and Evaluation of Analgesic, Anti-Inflammatory, Ulcerogenic Potential of Some 2-Pyrazoline Derivatives. Pharma Chemica, 4, 2012, 1679-1688.

Fioravanti R, Bolasco A, Manna F, Rossi F, Orallo F, Ortuso F, Alcaro S, Cirilli R, Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors. Eur J Med Chem, 45, 2010, 6135–6138.

Rajendra Prasad Y, Lakshmana Rao A, Prasoona L, Murali K, Ravi Kumar. Synthesis and antidepressant activity of some 1, 3, 5-triphenyl-2-pyrazolines and 3-(2"-hydroxy naphthalene-1"-yl)-1, 5-diphenyl-2-pyrazolines, Bio org. Med. Chem. Lett, 15, 2005, 5030-5034.